Log in

NASDAQ:NLNKNewLink Genetics Competitors & Alternatives

Notice: This company has been marked as potentially delisted and may not be actively trading.
$16.23
+0.08 (+0.50 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$15.96
Now: $16.23
$16.63
50-Day Range
$0.89
MA: $9.07
$14.10
52-Week Range
$0.82
Now: $16.23
$3.60
Volume13,773 shs
Average Volume547,540 shs
Market Capitalization$605.83 million
P/E RatioN/A
Dividend YieldN/A
Beta1.17

Competitors

NewLink Genetics (NASDAQ:NLNK) Vs. AMGN, GILD, CELG, VRTX, REGN, and BIIB

Should you be buying NLNK stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to NewLink Genetics, including Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and Biogen (BIIB).

Amgen (NASDAQ:AMGN) and NewLink Genetics (NASDAQ:NLNK) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.

Institutional & Insider Ownership

75.8% of Amgen shares are owned by institutional investors. Comparatively, 32.3% of NewLink Genetics shares are owned by institutional investors. 0.4% of Amgen shares are owned by insiders. Comparatively, 12.7% of NewLink Genetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Amgen and NewLink Genetics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amgen32.03%90.75%15.44%
NewLink Genetics-4,592.84%-41.50%-33.95%

Volatility and Risk

Amgen has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, NewLink Genetics has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500.

Earnings & Valuation

This table compares Amgen and NewLink Genetics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$23.36 billion6.50$7.84 billion$14.8217.43
NewLink Genetics$940,000.00644.50$-42,990,000.00($1.03)-15.76

Amgen has higher revenue and earnings than NewLink Genetics. NewLink Genetics is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Amgen and NewLink Genetics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amgen1111602.54
NewLink Genetics10001.00

Amgen currently has a consensus price target of $246.08, suggesting a potential downside of 4.71%. Given Amgen's stronger consensus rating and higher probable upside, analysts clearly believe Amgen is more favorable than NewLink Genetics.

Summary

Amgen beats NewLink Genetics on 11 of the 14 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and NewLink Genetics (NASDAQ:NLNK) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Institutional and Insider Ownership

80.2% of Gilead Sciences shares are owned by institutional investors. Comparatively, 32.3% of NewLink Genetics shares are owned by institutional investors. 0.1% of Gilead Sciences shares are owned by company insiders. Comparatively, 12.7% of NewLink Genetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Gilead Sciences and NewLink Genetics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gilead Sciences21.84%35.44%12.84%
NewLink Genetics-4,592.84%-41.50%-33.95%

Risk & Volatility

Gilead Sciences has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Comparatively, NewLink Genetics has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500.

Earnings and Valuation

This table compares Gilead Sciences and NewLink Genetics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$22.45 billion4.27$5.39 billion$6.1412.43
NewLink Genetics$940,000.00644.50$-42,990,000.00($1.03)-15.76

Gilead Sciences has higher revenue and earnings than NewLink Genetics. NewLink Genetics is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Gilead Sciences and NewLink Genetics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gilead Sciences3151002.25
NewLink Genetics10001.00

Gilead Sciences currently has a consensus price target of $79.6538, suggesting a potential upside of 4.33%. Given Gilead Sciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Gilead Sciences is more favorable than NewLink Genetics.

Summary

Gilead Sciences beats NewLink Genetics on 11 of the 14 factors compared between the two stocks.

Celgene (NASDAQ:CELG) and NewLink Genetics (NASDAQ:NLNK) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Institutional and Insider Ownership

71.7% of Celgene shares are owned by institutional investors. Comparatively, 32.3% of NewLink Genetics shares are owned by institutional investors. 0.4% of Celgene shares are owned by company insiders. Comparatively, 12.7% of NewLink Genetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Celgene and NewLink Genetics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Celgene34.63%78.15%18.54%
NewLink Genetics-4,592.84%-41.50%-33.95%

Risk & Volatility

Celgene has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500. Comparatively, NewLink Genetics has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500.

Earnings and Valuation

This table compares Celgene and NewLink Genetics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Celgene$15.28 billion5.04$4.05 billion$7.6114.22
NewLink Genetics$940,000.00644.50$-42,990,000.00($1.03)-15.76

Celgene has higher revenue and earnings than NewLink Genetics. NewLink Genetics is trading at a lower price-to-earnings ratio than Celgene, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Celgene and NewLink Genetics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Celgene06002.00
NewLink Genetics10001.00

Celgene currently has a consensus price target of $105.60, suggesting a potential downside of 2.44%. Given Celgene's stronger consensus rating and higher probable upside, equities analysts plainly believe Celgene is more favorable than NewLink Genetics.

Summary

Celgene beats NewLink Genetics on 11 of the 13 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and NewLink Genetics (NASDAQ:NLNK) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Institutional and Insider Ownership

93.4% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 32.3% of NewLink Genetics shares are owned by institutional investors. 0.7% of Vertex Pharmaceuticals shares are owned by company insiders. Comparatively, 12.7% of NewLink Genetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Vertex Pharmaceuticals and NewLink Genetics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vertex Pharmaceuticals31.35%25.69%18.50%
NewLink Genetics-4,592.84%-41.50%-33.95%

Risk & Volatility

Vertex Pharmaceuticals has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. Comparatively, NewLink Genetics has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500.

Earnings and Valuation

This table compares Vertex Pharmaceuticals and NewLink Genetics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$4.16 billion18.13$1.18 billion$4.2967.86
NewLink Genetics$940,000.00644.50$-42,990,000.00($1.03)-15.76

Vertex Pharmaceuticals has higher revenue and earnings than NewLink Genetics. NewLink Genetics is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Vertex Pharmaceuticals and NewLink Genetics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vertex Pharmaceuticals072112.79
NewLink Genetics10001.00

Vertex Pharmaceuticals currently has a consensus price target of $284.2308, suggesting a potential downside of 2.36%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Vertex Pharmaceuticals is more favorable than NewLink Genetics.

Summary

Vertex Pharmaceuticals beats NewLink Genetics on 12 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and NewLink Genetics (NASDAQ:NLNK) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Earnings and Valuation

This table compares Regeneron Pharmaceuticals and NewLink Genetics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion8.71$2.12 billion$21.4728.99
NewLink Genetics$940,000.00644.50$-42,990,000.00($1.03)-15.76

Regeneron Pharmaceuticals has higher revenue and earnings than NewLink Genetics. NewLink Genetics is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Regeneron Pharmaceuticals and NewLink Genetics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals28.56%24.94%18.81%
NewLink Genetics-4,592.84%-41.50%-33.95%

Institutional and Insider Ownership

68.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 32.3% of NewLink Genetics shares are owned by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are owned by company insiders. Comparatively, 12.7% of NewLink Genetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk & Volatility

Regeneron Pharmaceuticals has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Comparatively, NewLink Genetics has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Regeneron Pharmaceuticals and NewLink Genetics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals0131312.56
NewLink Genetics10001.00

Regeneron Pharmaceuticals currently has a consensus price target of $557.7037, suggesting a potential downside of 10.40%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Regeneron Pharmaceuticals is more favorable than NewLink Genetics.

Summary

Regeneron Pharmaceuticals beats NewLink Genetics on 12 of the 15 factors compared between the two stocks.

NewLink Genetics (NASDAQ:NLNK) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations and risk.

Earnings & Valuation

This table compares NewLink Genetics and Biogen's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NewLink Genetics$940,000.00644.50$-42,990,000.00($1.03)-15.76
Biogen$14.38 billion3.01$5.89 billion$33.577.90

Biogen has higher revenue and earnings than NewLink Genetics. NewLink Genetics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares NewLink Genetics and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NewLink Genetics-4,592.84%-41.50%-33.95%
Biogen40.76%49.22%24.26%

Institutional and Insider Ownership

32.3% of NewLink Genetics shares are owned by institutional investors. Comparatively, 87.5% of Biogen shares are owned by institutional investors. 12.7% of NewLink Genetics shares are owned by company insiders. Comparatively, 0.5% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

NewLink Genetics has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for NewLink Genetics and Biogen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NewLink Genetics10001.00
Biogen517902.13

Biogen has a consensus target price of $308.5926, suggesting a potential upside of 16.40%. Given Biogen's stronger consensus rating and higher probable upside, analysts clearly believe Biogen is more favorable than NewLink Genetics.

Summary

Biogen beats NewLink Genetics on 11 of the 14 factors compared between the two stocks.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.2$258.24+1.2%$151.91 billion$23.36 billion20.24Analyst Revision
Gilead Sciences logo
GILD
Gilead Sciences
2.0$76.35+0.4%$95.77 billion$22.45 billion19.63Analyst Revision
Celgene logo
CELG
Celgene
1.7$108.24+0.0%$77.04 billion$15.28 billion14.22
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
1.4$291.10+1.7%$75.48 billion$4.16 billion50.45
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
1.4$622.45+2.1%$68.48 billion$7.86 billion31.28Increase in Short Interest
Biogen logo
BIIB
Biogen
1.9$265.12+0.1%$43.26 billion$14.38 billion8.18
Seattle Genetics logo
SGEN
Seattle Genetics
1.3$169.03+0.9%$29.26 billion$916.71 million-89.91Insider Selling
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
2.3$112.30+0.1%$24.80 billion$4.99 billion10.57Analyst Revision
Incyte logo
INCY
Incyte
1.4$106.47+3.6%$23.14 billion$2.16 billion-60.84
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.7$126.78+0.7%$22.93 billion$1.70 billion207.84Analyst Revision
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.5$149.87+0.7%$17.29 billion$219.75 million-18.66
EXACT Sciences logo
EXAS
EXACT Sciences
1.6$86.66+0.9%$12.99 billion$876.29 million-111.10
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
1.8$125.37+0.4%$11.64 billion$788.10 million68.14
Immunomedics logo
IMMU
Immunomedics
1.9$37.54+1.7%$8.67 billion$290,000.00-20.51
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.4$60.79+1.0%$8.47 billion$1.12 billion55.26
Exelixis logo
EXEL
Exelixis
1.9$23.48+0.1%$7.20 billion$967.78 million25.25Increase in Short Interest
Repligen logo
RGEN
Repligen
1.2$126.65+1.9%$6.62 billion$270.24 million281.45Decrease in Short Interest
United Therapeutics logo
UTHR
United Therapeutics
1.7$120.33+0.6%$5.30 billion$1.45 billion10.04
Novavax logo
NVAX
Novavax
1.2$81.64+2.4%$4.73 billion$18.66 million-19.72Analyst Revision
Emergent Biosolutions logo
EBS
Emergent Biosolutions
1.2$84.08+2.6%$4.41 billion$1.11 billion64.68
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$15.55+0.0%$4.01 billion$182.24 million-11.96Analyst Revision
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.6$28.51+3.9%$3.87 billion$195.99 million-51.84
Momenta Pharmaceuticals logo
MNTA
Momenta Pharmaceuticals
1.6$32.27+1.5%$3.80 billion$23.87 million-11.52
ChemoCentryx logo
CCXI
ChemoCentryx
1.5$58.01+0.2%$3.59 billion$36.13 million-53.22Increase in Short Interest
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$63.10+1.0%$3.18 billion$806.43 million-9.77
Alkermes logo
ALKS
Alkermes
1.1$19.59+0.9%$3.11 billion$1.17 billion-22.26
Opko Health logo
OPK
Opko Health
1.7$3.54+3.1%$2.37 billion$901.90 million-7.38Analyst Upgrade
Increase in Short Interest
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.4$111.64+0.2%$1.79 billion$120.28 million-32.45
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.8$111.58+0.6%$1.72 billionN/A-16.38
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.18+0.1%$1.62 billion$428.41 million19.21Analyst Downgrade
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.8$47.09+1.2%$1.55 billion$252 million-4.39Analyst Revision
Innoviva logo
INVA
Innoviva
0.9$13.99+0.4%$1.42 billion$261.02 million8.18
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.4$9.63+2.6%$1.36 billion$102.43 million-11.60
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.7$5.02+2.2%$885.53 million$48.83 million-5.34
Myriad Genetics logo
MYGN
Myriad Genetics
1.4$11.58+2.8%$863.35 million$851.10 million-5.79Increase in Short Interest
ImmunoGen logo
IMGN
ImmunoGen
1.4$4.88+2.7%$851.12 million$82.27 million-8.41
Dynavax Technologies logo
DVAX
Dynavax Technologies
2.1$8.67+4.2%$799.24 million$35.22 million-4.71
Codexis logo
CDXS
Codexis
1.5$12.07+3.3%$712.35 million$68.46 million-48.28
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.6$3.24+0.9%$694.29 million$150,000.00-4.63Analyst Revision
Agenus logo
AGEN
Agenus
1.5$4.02+0.0%$672.87 million$150.05 million-3.24
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
2.0$11.85+0.7%$646.42 million$227.19 million5.54Increase in Short Interest
Molecular Templates logo
MTEM
Molecular Templates
1.6$13.51+0.1%$617.81 million$22.27 million-6.23
Clovis Oncology logo
CLVS
Clovis Oncology
1.7$6.61+1.2%$508.32 million$143.01 million-0.92Analyst Downgrade
BioSpecifics Technologies logo
BSTC
BioSpecifics Technologies
1.9$62.42+1.4%$458.47 million$38.19 million18.74
Geron logo
GERN
Geron
1.2$2.17+0.9%$441.20 million$460,000.00-5.56Analyst Downgrade
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.43+7.6%$399.49 million$109.33 million-2.86Analyst Upgrade
MannKind logo
MNKD
MannKind
1.9$1.79+5.6%$381.52 million$63.04 million-7.78
Progenics Pharmaceuticals logo
PGNX
Progenics Pharmaceuticals
1.5$4.10+0.0%$355.05 million$34.99 million-5.32High Trading Volume
PDL BioPharma logo
PDLI
PDL BioPharma
1.0$2.91+2.4%$339.15 million$54.76 million-3.10
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.5$1.91+6.8%$321.97 million$59.29 million-11.94
This page was last updated on 7/6/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.